Xvivo Perfusion AB (publ)
XVIPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.06 | 0.27 | 2.82 | -8.44 |
| FCF Yield | 0.28% | -1.01% | -1.63% | -1.31% |
| EV / EBITDA | 48.25 | 113.39 | 156.96 | 195.96 |
| Quality | ||||
| ROIC | 3.40% | 0.20% | 0.33% | -1.57% |
| Gross Margin | 74.95% | 74.49% | 71.51% | 72.87% |
| Cash Conversion Ratio | 0.56 | 0.50 | 1.25 | -1.81 |
| Growth | ||||
| Revenue 3-Year CAGR | 25.58% | 32.24% | 32.17% | 5.37% |
| Free Cash Flow Growth | 141.54% | 5.28% | 2.87% | -37.94% |
| Safety | ||||
| Net Debt / EBITDA | -1.32 | -6.39 | -6.11 | -10.03 |
| Interest Coverage | -1.43 | 3.52 | 10.59 | -67.02 |
| Efficiency | ||||
| Inventory Turnover | 0.91 | 1.08 | 1.11 | 0.90 |
| Cash Conversion Cycle | 391.66 | 312.68 | 297.77 | 376.54 |